Literature DB >> 30902029

Exercise as a therapeutic intervention for people with cystic fibrosis.

Nathan Ward1,2, Kathy Stiller3, Anne E Holland4.   

Abstract

INTRODUCTION: The complex multisystem nature of cystic fibrosis (CF) commonly results in reduced exercise tolerance, which is independently associated with poor clinical outcomes. Exercise is routinely recommended as part of the therapeutic regimen in CF to improve both respiratory and non-respiratory impairments. Areas covered: This article summarises the most recent evidence regarding the use of exercise as a therapeutic intervention in CF and discusses some of the practical considerations for exercise prescription in this setting. Clinical trials in progress and future research priorities are outlined. Expert opinion: On the balance of available evidence, exercise is likely to assist in improving physical fitness and health-related quality of life (HRQOL) and may be associated with a slower rate of decline in respiratory function in CF. Limitations to current studies include small sample sizes, study durations insufficient to achieve a training effect and difficulty distinguishing the effects of exercise training from that of other interventions implemented as part of a package of care. Larger, multi-centred trials are required to clarify the role of exercise in CF in improving physical fitness, respiratory function, HRQOL, as a substitute for traditional airway clearance techniques and in the management of common CF-related comorbidities.

Entities:  

Keywords:  Cystic fibrosis; exercise therapy; physical therapy modalities

Mesh:

Year:  2019        PMID: 30902029     DOI: 10.1080/17476348.2019.1598861

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  6 in total

Review 1.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

2.  Individualized physical training in the therapy of Primary Ciliary Dyskinesia - A case report.

Authors:  Moritz Schumann; Nils Freitag; Eva Haag; Wilhelm Bloch
Journal:  Respir Med Case Rep       Date:  2019-08-16

3.  Physiotherapists' use of airway clearance techniques during an acute exacerbation of bronchiectasis: a survey study.

Authors:  Jennifer Phillips; Annemarie Lee; Rodney Pope; Wayne Hing
Journal:  Arch Physiother       Date:  2021-02-01

Review 4.  Toward the Establishment of New Clinical Endpoints for Cystic Fibrosis: The Role of Lung Clearance Index and Cardiopulmonary Exercise Testing.

Authors:  Elpis Hatziagorou; Asterios Kampouras; Vasiliki Avramidou; Ilektra Toulia; Elisavet-Anna Chrysochoou; Maria Galogavrou; Fotios Kirvassilis; John Tsanakas
Journal:  Front Pediatr       Date:  2021-02-25       Impact factor: 3.418

5.  Effects of a Long-Term Wearable Activity Tracker-Based Exercise Intervention on Cardiac Morphology and Function of Patients with Cystic Fibrosis.

Authors:  Maria Anifanti; Stavros Giannakoulakos; Elpis Hatziagorou; Asterios Kampouras; John Tsanakas; Asterios Deligiannis; Evangelia Kouidi
Journal:  Sensors (Basel)       Date:  2022-06-28       Impact factor: 3.847

6.  Physical Fitness-Not Physical Activity Levels-Influence Quality of Life in Anorexia Nervosa.

Authors:  Alexa Agne; Hugo Olmedillas; Margarita Pérez Ruiz; Miguel del Valle Soto; Maria Fernandez-del-Valle
Journal:  Int J Environ Res Public Health       Date:  2022-02-25       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.